An absorption-type merger between the U.S. subsidiaries of Aadi Bioscience, Inc. and KAKEN INVESTMENTS INC., planned for the first half of FY2027, with Aadi Bioscience, Inc. as the surviving company and KAKEN INVESTMENTS INC. as the absorbed company. This is an individual organizational restructuring project intended to combine the two companies’ management resources, improve operating efficiency and enhance corporate value.